Frigault, M. J., Maziarz, R. T., Park, J. H., Lazaryan, A., Shah, N. N., Svoboda, J., Lekakis, L. J., Reshef, R., Phillips, C. L., Burke, L., Lei, J., Pratta, M., Morariu-Zamfir, R., & DiPersio, J. F. (2025). Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. Blood Journal. https://doi.org/10.1182/blood.2024026586

Zhang, C., Zhao, N., Khan, R., Hung, M., Zhang, C., Wang, S., Wang, T. J. C., & Lin, C. (2024). The prognostic significance of androgen receptor expression in gliomas. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-72284-4

Viani, K., Furlong, W., Filho, V. O., Santos Murra, M. dos, Nabarrete, J. M., Ladas, E., & Barr, R. D. (2024). Comprehensive health status and health-related quality of life of children at diagnosis of high-risk neuroblastoma: a multicentric pilot study. Hematology, Transfusion and Cell Therapy. https://doi.org/10.1016/j.htct.2024.05.014

Crawford, J. R., Lo, Y. Y., Pagadala, M. S., Chapman, O. S., Sridhar, S., Juarez, E. F., Tzaridis, T., Chau, L. Q., Wang, J., Eisemann, T., Masihi, M. B., Chambers, K. R., Dixit, D., Koubourli, D., Larson, J. D., Guidugli, L., Hammer, M., Wong, T., Abdullaev, Z., … Wechsler-Reya, R. J. (2024). TRLS-13. MULTI-OMICS AND FUNCTIONAL PRECISION MEDICINE FOR NEWLY DIAGNOSED AND RECURRENT PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.166

Hu, X., Bukhari, S. M., Tymm, C., Adam, K., Lerrer, S., Henick, B. S., Winchester, R. J., & Mor, A. (2024). Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. Journal for ImmunoTherapy of Cancer, 12(3), e008482. https://doi.org/10.1136/jitc-2023-008482

Arrillaga-Romany, I., Gardner, S. L., Odia, Y., Aguilera, D., Allen, J. E., Batchelor, T., Butowski, N., Chen, C., Cloughesy, T., Cluster, A., de Groot, J., Dixit, K. S., Graber, J. J., Haggiagi, A. M., Harrison, R. A., Kheradpour, A., Kilburn, L. B., Kurz, S. C., Lu, G., … Wen, P. Y. (2024). ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal of Clinical Oncology, 42(13), 1542–1552. https://doi.org/10.1200/jco.23.01134

Banerjee, D., Boboila, S., Okochi, S., Angelastro, J. M., Kadenhe-Chiweshe, A. V., Lopez, G., Califano, A., Connolly, E. P., Greene, L. A., & Yamashiro, D. J. (2023). Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance. Cancer Research Communications, 3(12), 2518–2530. https://doi.org/10.1158/2767-9764.crc-23-0154

Schultz, K. A. P., Chintagumpala, M., Piao, J., Chen, K. S., Shah, R., Gartrell, R. D., Christison-Lagay, E., Pashnakar, F., Berry, J. L., O’Neill, A. F., Vasta, L. M., Flynn, A., Mitchell, S. G., Seynnaeve, B. KN., Rosenblum, J., Potter, S. L., Kamihara, J., Rodriguez-Galindo, C., Hawkins, D. S., & Laetsch, T. W. (2023). Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective. EJC Paediatric Oncology, 2, 100024. https://doi.org/10.1016/j.ejcped.2023.100024

Lee, E., O’Keefe, S., Leong, A., Park, H.-R., Varadarajan, J., Chowdhury, S., Hiner, S., Kim, S., Shiva, A., Friedman, R. A., Remotti, H., Fojo, T., Yang, H. W., Thurston, G., & Kim, M. (2023). Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment. Journal of Clinical Investigation, 133(20). https://doi.org/10.1172/jci167994

Safari, M., Scotto, L., Litman, T., Petrukhin, L. A., Zhu, H., Shen, M., Robey, R. W., Hall, M. D., Fojo, T., & Bates, S. E. (2023). Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms. Cancers, 15(20), 4960. https://doi.org/10.3390/cancers15204960

Kimura, N., Hirata, Y., Iwashiro, N., Kijima, H., Takayasu, S., Yamagata, S., Sakihara, S., Uchino, S., & Ohara, M. (2023). Multiple endocrine neoplasia type 1 with Zollinger–Ellison syndrome: clinicopathological analysis of a Japanese family with focus on menin immunohistochemistry. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1221514

Boboila, S., Okochi, S., Banerjee, D., Barton, S., Street, C., Zenilman, A. L., Wang, Q., Gartrell, R. D., Saenger, Y. M., Welch, D., Wu, C.-C., Kadenhe-Chiweshe, A., Yamashiro, D. J., & Connolly, E. P. (2023). Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma. Heliyon, 9(6), e17399. https://doi.org/10.1016/j.heliyon.2023.e17399

Laderian, B., Wei, W., Farha, N., Mundi, P., Rao, P., Balagamwala, E., Steele, S., Vijayvergia, N., Sadaps, M., Chandrasekharan, C., Mohamed, A., & Pacak, K. (2023). P-136 Increased healthcare costs due to diagnostic imaging services following false elevation of plasma chromogranin A and 24-hour urinary 5-hydroxyindoleacetic acid: A quality improvement project. Annals of Oncology, 34, S63. https://doi.org/10.1016/j.annonc.2023.04.192

Parejo-Alonso, B., Royo-García, A., Espiau-Romera, P., Courtois, S., Curiel-García, Á., Zagorac, S., Villaoslada, I., Olive, K. P., Heeschen, C., & Sancho, P. (2023). Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. Biomedicine & Pharmacotherapy, 158, 114162. https://doi.org/10.1016/j.biopha.2022.114162

Arrillaga-Romany, I., Lassman, A., McGovern, S., Mueller, S., Nabors, L. B., van den Bent, M., Vogelbaum, M., Allen, J. E., Melemed, A., Tarapore, R., Yang, D., Wen, P. Y., & Cloughesy, T. (2022). RTID-01. ONC108: A RANDOMIZED PHASE 3 STUDY OF ONC201 IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA. Neuro-Oncology, 24(Supplement_7), vii249–vii249. https://doi.org/10.1093/neuonc/noac209.961

Macy, M., Cash, T., Pinto, N., Pressey, J. G., Szalontay, L., Furman, W. L., Bukowinski, A., Foster, J. H., Friedman, G. K., HaDuong, J., Fox, E., Weigel, B. J., Grevel, J., Huang, F., Phelps, C., Childs, B. H., Chung, J., Chaturvedi, S., Schulz, A., & DuBois, S. G. (2022). Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. European Journal of Cancer, 174, S28–S29. https://doi.org/10.1016/s0959-8049(22)00878-4

Rosenblat, T. L., McDevitt, M. R., Carrasquillo, J. A., Pandit-Taskar, N., Frattini, M. G., Maslak, P. G., Park, J. H., Douer, D., Cicic, D., Larson, S. M., Scheinberg, D. A., & Jurcic, J. G. (2022). Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clinical Cancer Research, 28(10), 2030–2037. https://doi.org/10.1158/1078-0432.ccr-21-3712

Brat, D. J., Aldape, K., Bridge, J. A., Canoll, P., Colman, H., Hameed, M. R., Harris, B. T., Hattab, E. M., Huse, J. T., Jenkins, R. B., Lopez-Terrada, D. H., McDonald, W. C., Rodriguez, F. J., Souter, L. H., Colasacco, C., Thomas, N. E., Yount, M. H., van den Bent, M. J., & Perry, A. (2022). Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Archives of Pathology & Laboratory Medicine, 146(5), 547–574. https://doi.org/10.5858/arpa.2021-0295-cp

Çoku, J., Booth, D. M., Skoda, J., Pedrotty, M. C., Vogel, J., Liu, K., Vu, A., Carpenter, E. L., Ye, J. C., Chen, M. A., Dunbar, P., Scadden, E., Yun, T. D., Nakamaru‐Ogiso, E., Area‐Gomez, E., Li, Y., Goldsmith, K. C., Reynolds, C. P., Hajnoczky, G., & Hogarty, M. D. (2022). Reduced ER–mitochondria connectivity promotes neuroblastoma multidrug resistance. The EMBO Journal, 41(8). Portico. https://doi.org/10.15252/embj.2021108272

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776